Vanguard Group Inc. Acquires 344,080 Shares of Kymera Therapeutics, Inc. $KYMR

Key Points

• Vanguard Group Inc. has increased its stake in Kymera Therapeutics by 7.0%, holding approximately 8.03% of the company, valued at $143.18 million.
• Kymera Therapeutics reported a quarterly loss of ($0.95) EPS, missing analyst estimates, with revenue down 55.1% year-on-year.
• Analysts have set a consensus target price of $59.11 for Kymera Therapeutics, with several firms rating the stock as a "Buy" or "Strong Buy."

Vanguard Group Inc. increased its stake in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 7.0% during the first quarter, according to the company in its most recent filing with the SEC. The fund owned 5,231,392 shares of the company's stock after acquiring an additional 344,080 shares during the period. Vanguard Group Inc. owned 8.03% of Kymera Therapeutics worth $143,183,000 as of its most recent filing with the SEC.

A number of other hedge funds have also made changes to their positions in the stock. GSA Capital Partners LLP increased its holdings in shares of Kymera Therapeutics by 6.8% during the 1st quarter. GSA Capital Partners LLP now owns 31,537 shares of the company's stock valued at $863,000 after acquiring an additional 1,997 shares during the last quarter. Neo Ivy Capital Management acquired a new position in shares of Kymera Therapeutics during the 1st quarter valued at about $395,000. KBC Group NV increased its holdings in shares of Kymera Therapeutics by 15.2% during the 1st quarter. KBC Group NV now owns 2,479 shares of the company's stock valued at $68,000 after acquiring an additional 328 shares during the last quarter. Rhumbline Advisers boosted its stake in Kymera Therapeutics by 9.0% during the 1st quarter. Rhumbline Advisers now owns 69,928 shares of the company's stock valued at $1,914,000 after purchasing an additional 5,771 shares during the period. Finally, GAMMA Investing LLC boosted its stake in Kymera Therapeutics by 3,851.5% during the 1st quarter. GAMMA Investing LLC now owns 6,678 shares of the company's stock valued at $183,000 after purchasing an additional 6,509 shares during the period.

Kymera Therapeutics Price Performance

Shares of Kymera Therapeutics stock traded up $2.05 during midday trading on Tuesday, hitting $43.87. 435,439 shares of the company were exchanged, compared to its average volume of 644,257. The firm has a market cap of $3.14 billion, a P/E ratio of -12.64 and a beta of 2.18. Kymera Therapeutics, Inc. has a 52 week low of $19.44 and a 52 week high of $53.27. The firm has a 50 day simple moving average of $44.02 and a 200-day simple moving average of $36.67.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last posted its earnings results on Monday, August 11th. The company reported ($0.95) EPS for the quarter, missing the consensus estimate of ($0.83) by ($0.12). The company had revenue of $11.48 million for the quarter, compared to the consensus estimate of $17.37 million. Kymera Therapeutics had a negative return on equity of 31.60% and a negative net margin of 616.03%.Kymera Therapeutics's quarterly revenue was down 55.1% compared to the same quarter last year. During the same quarter last year, the business earned ($0.58) EPS. Equities research analysts expect that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on KYMR shares. B. Riley upgraded Kymera Therapeutics to a "strong-buy" rating and set a $60.00 target price for the company in a research note on Wednesday, July 30th. Bank of America upgraded Kymera Therapeutics from a "neutral" rating to a "buy" rating and set a $51.00 target price for the company in a research note on Monday, June 2nd. UBS Group decreased their target price on Kymera Therapeutics from $72.00 to $70.00 and set a "buy" rating for the company in a research note on Tuesday, May 13th. Stifel Nicolaus started coverage on Kymera Therapeutics in a research note on Tuesday, May 20th. They set a "buy" rating and a $55.00 target price for the company. Finally, The Goldman Sachs Group upgraded Kymera Therapeutics to a "strong-buy" rating in a research note on Tuesday, July 15th. Three analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and one has given a Hold rating to the company's stock. Based on data from MarketBeat, Kymera Therapeutics presently has an average rating of "Buy" and a consensus price target of $58.76.

Insider Buying and Selling

In related news, Director Jeffrey W. Albers sold 6,349 shares of Kymera Therapeutics stock in a transaction on Tuesday, June 3rd. The stock was sold at an average price of $49.00, for a total transaction of $311,101.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Nello Mainolfi sold 30,000 shares of Kymera Therapeutics stock in a transaction on Tuesday, June 3rd. The stock was sold at an average price of $49.00, for a total value of $1,470,000.00. Following the sale, the chief executive officer directly owned 660,482 shares of the company's stock, valued at approximately $32,363,618. This trade represents a 4.34% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 48,349 shares of company stock worth $2,334,301. 16.01% of the stock is currently owned by company insiders.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.